Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Henriksson, Eva ^a   Kjellén, Elisabeth ^a   Baldetorp, Bo ^a   Bendahl, Pär Ola ^a   Borg, Åke ^a   Brun, Eva ^a   Mertens, Fredrik ^a   Ohlsson, Tomas ^a   Rennstam, Karin ^a   Wennerberg, Johan ^a   Wahlberg, Peter ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CRYSTAL VIOLET; CYCLIN D1; FLUORODEOXYGLUCOSE F 18; PROTEIN P53; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOMA CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DNA SEQUENCE; DRUG SENSITIVITY; DRUG UPTAKE; EXPLANT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KARYOTYPE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TISSUE CULTURE; CHROMOSOME BANDING PATTERN; DOSE RESPONSE; DRUG SCREENING; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOME BANDING; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; RADIOPHARMACEUTICALS;

EID: 62149141374     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-17     Document Type: Article

References (31)

1. Estimates of cancer incidence and mortality in Europe in 2006. JAM Ferley M Boniol M Heanue M Colombet P Boyle, Annals of Oncology 2007 18 582 92 17287242
2. Head and neck cancer. EE Vokes RR Weichselbaum SM Lippman WK Hong, N Engl J Med 1993 3 184 94 10.1056/NEJM199301213280306
3. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. JP Pignon J Bourhis C Domenge L Designe, Lancet 2000 355 9208 949 55 10768432
4. Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm. B Baldetorp M Dalberg U Holst G Lindgren, Cytometry 1989 6 695 705 10.1002/cyto.990100605
5. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. B Schutte MM Reynders FT Bosman GH Blijham, Cytometry 1985 6 1 26 30 10.1002/cyto.990060106 3967551
6. Complex karyotype with an 11q13 homogeneously staining region in esophageal squamous cell carcinoma. C Jin F Mertens Y Jin J Wennerberg S Heim F Mitelman, Cancer Genet Cytogenet 1995 82 2 175 6 10.1016/0165-4608(95)00039-R 7664250
7. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. MM Tanner M Tirkkonen A Kallioniemi C Collins T Stokke R Karhu D Kowbel F Shadravan M Hintz W Kuo FM Waldman JJ Isola, Cancer Res 1994 54 16 4257 60 8044767
8. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. T Fioretos B Strombeck T Sandberg B Johansson R Billstrom A Borg PG Nilsson HVD Berghe A Hagemeijer F Mitelman M Höglund, Blood 1999 94 1 225 32 10381517
9. Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. E Henriksson E Kjellen P Wahlberg J Wennerberg JH Kjellstrom, In Vitro Cell Dev Biol Anim 2006 42 10 320 3 17316066
10. Permanent in vitro growth is associated with poor prognosis in head and neck cancer. K Pekkola A Raikka H Joensuu H Minn K Aitasalo R Grenman, Acta Otolaryngol 2004 124 2 192 6 10.1080/00016480310015209 15072423
11. Cloning efficiency. A possible prognostic indicator in squamous cell carcinoma of head and neck. ME Johns MS Mills, Cancer 1983 52 8 1401 4 10.1002/1097-0142(19831015)52:8<1401::AID-CNCR2820520811>3.0.CO;2-7 6616405
12. The clonal assay of head and neck tumor cells: results and clinical correlations. M Johns, Laryngoscope 1982 92 7 Pt 2 Suppl 28 1 26 10.1288/00005537-198207001-00001 7087657
13. Establishment and characterization of nine new head and neck cancer cell lines. SYCK Kim HR Lee KS Lee TE Carey, Acta Otolaryngol 1997 117 5 775 84 10.3109/00016489709113477 9349880
14. Factors that influence growth of head and neck squamous carcinoma in the soft agar cloning assay. DE Mattox DD Von Hoff GM Clark TB Aufdemorte, Cancer 1984 53 8 1736 40 10.1002/1097-0142(19840415)53:8<1736::AID- CNCR2820530820>3.0.CO;2-1 6697312
15. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. JA Akervall Y Jin JP Wennerberg UK Zatterstrom E Kjellen F Mertens J Wennerberg, Cancer 1995 76 5 853 9 10.1002/1097-0142(19950901)76:5<853::AID- CNCR2820760520>3.0.CO;2-6 8625189
16. Analysis of DNA ploidy using fresh frozen tissues of head and neck squamous cell carcinomas. Y Arai M Tsukuda K Ito H Enomoto M Furukawa A Kubota S Yanoma N Okamoto, Auris Nasus Larynx 1997 24 2 193 8 10.1016/S0385-8146(96) 00018-1 9134143
17. Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base. P Rubio Bueno L Naval Gias R Garcia Delgado J Domingo Cebollada FJ Diaz Gonzalez, Head & Neck 1998 20 3 232 39 10.1002/(SICI)1097-0347(199805)20:3<232::AID-HED8>3.0.CO;2-1 9570629
18. DNA flow cytometry as a prognostic indicator in head and neck cancer. MM Goldsmith DH Cresson LA Arnold DS Postma FB Askin HC Pillsbury, Otolaryngol Head Neck Surg 1987 96 4 307 18 3108817
19. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. GR Borst JS Belderbos R Boellaard EF Comans K De Jaeger AA Lammertsma JV Lebesque, Eur J Cancer 2005 41 11 1533 41 10.1016/j.ejca.2005.03. 026 15953716
20. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. C Sperti C Pasquali F Chierichetti A Ferronato G Decet S Pedrazzoli, J Gastrointest Surg 2003 7 8 953 9 discussion 59-60. 10.1016/j.gassur.2003.09.002 14675704
21. FDG-PET. A possible prognostic factor in head and neck cancer. W Halfpenny SF Hain L Biassoni MN Maisey JA Sherman M McGurk, Br J Cancer 2002 86 4 512 6 10.1038/sj.bjc.6600114 11870529
22. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. M Kunkel TE Reichert P Benz HA Lehr JH Jeong S Wieand P Bartenstein W Wagner TL Whiteside, Cancer 2003 97 4 1015 24 10.1002/cncr.11159 12569601
23. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. E Brun E Kjellen J Tennvall T Ohlsson A Sandell R Perfekt J Wennerberg SE Strand, Head Neck 2002 24 2 127 35 10.1002/hed.10037 11891942
24. Positron emission imaging of head and neck cancer, including thyroid carcinoma. H Schoder HW Yeung, Semin Nucl Med 2004 34 3 180 97 10.1053/j.semnuclmed.2004.03.004 15202100
25. Proliferation is associated with 2-deoxy-D-[1-3H]glucose uptake by T47D breast tumour and SW480 and SW620 colonic tumour cells. TA Smith JC Titley VR McCready, Nucl Med Biol 1998 25 5 481 5 10.1016/S0969-8051(98)00014-6 9720666
26. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. H Minn H Joensuu A Ahonen P Klemi, Cancer 1988 61 9 1776 81 10.1002/1097-0142(19880501)61:9<1776::AID-CNCR2820610909>3.0.CO;2-7 3355975
27. Deoxyglucose uptake by a head and neck squamous carcinoma: influence of changes in proliferative fraction. TA Smith J Titley, Int J Radiat Oncol Biol Phys 2000 47 1 219 23 10758327
28. [Fluorine-18] fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. R Jacob HJ Welkoborsky WJ Mann M Jauch R Amedee, ORL J Otorhinolaryngol Relat Spec 2001 63 5 307 13 11528276
29. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. K Watanabe H Nomori T Ohtsuka T Naruke A Ebihara H Orikasa K Yamazaki K Uno T Kobayashi T Goya, Jpn J Clin Oncol 2006 36 7 403 9 10.1093/jjco/hyl043 16782729
30. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. TA Smith RI Sharma AM Thompson FE Paulin, J Nucl Med 2006 47 9 1525 30 16954562
31. Mitochondrial impairment in p53-deficient human cancer cells. S Zhou S Kachhap KK Singh, Mutagenesis 2003 18 3 287 92 10.1093/mutage/18.3.287 12714696